title: Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion.
abstract: The combined effects of continuous low dose rate irradiation (CLDRI) and concurrent infusion of bleomycin, cyclophosphamide, cis-platinum, 5-fluorouracil, actinomycin D, and mitomycin C were studied in the SCC VII/SF tumor, a squamous cell carcinoma and the jejunal crypt cells in the mouse. For the SCC VII/SF tumor, enhanced cell killing was seen with each of the six drugs when infused concurrently with CLDRI; the greatest enhancement was seen with mitomycin C and cis-platinum. For the jejunal crypt cells, enhanced cell killing was seen primarily with bleomycin. At a dose of 20 Gy, the dose effect factor (DEF) ranged from 1.13-1.64 for the SCC VII/SF tumor and 0.92-1.19 for the jejunal crypt cells. Our results suggest a therapeutic gain with concurrent CLDRI and chemotherapy infusion for five of the six chemotherapeutic drugs studied with the exception of bleomycin.
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002588:Cesium Radioisotopes / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005472:Fluorouracil / Q000627:therapeutic use; D008297:Male; D051379:Mice; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D014916:Whole-Body Irradiation
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D002588:Cesium Radioisotopes; D008937:Mitomycins; D001761:Bleomycin; D003609:Dactinomycin; D016685:Mitomycin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil